Filter
304
Text search:
mRNA
Featured
Recommendations
56
New Publications
8
Language
Document type
Guidelines
99
Fact sheets
64
Studies & Reports
38
No document type
32
Videos
29
Manuals
11
Resource Platforms
11
Strategic & Response Plan
8
Training Material
5
Infographics
3
Situation Updates
2
Brochures
1
Online Courses
1
Countries / Regions
Germany
23
Brazil
16
Russia
12
Global
10
Ukraine
8
Middle East and North Africa
7
Latin America and the Carribbean
7
India
6
Nigeria
4
Syria
4
Ecuador
4
Yemen
4
Lebanon
3
Mozambique
3
Argentina
3
Eastern Europe
3
Senegal
2
Mali
2
Uganda
2
Niger
2
Haiti
2
Somalia
2
South Sudan
2
China
2
South Africa
2
Sudan
2
Peru
2
Chile
2
Western and Central Europe
2
Africa
2
Kazakhstan
2
Belarus
2
Burkina Faso
1
Sierra Leone
1
Liberia
1
Congo, Democratic Republic of
1
Côte d’Ivoire / Ivory Coast
1
Morocco
1
Saudi Arabia
1
Ethiopia
1
Cameroon
1
Iraq
1
Jordan
1
Egypt
1
Chad
1
Kenya
1
Rwanda
1
Indonesia
1
Mauritania
1
Benin
1
Dominican Republic
1
Cuba
1
Colombia
1
Honduras
1
El Salvador
1
Bolivia
1
Libya
1
Angola
1
Guatemala
1
Madagascar
1
Mexico
1
Nicaragua
1
East and Southern Africa
1
West and Central Africa
1
South–East Asia Region
1
Paraguay
1
Venezuela
1
Congo-Brazzaville
1
Qatar
1
France
1
Tunisia
1
United Kingdom
1
Spain
1
Israel
1
Authors & Publishers
Publication Years
Category
Countries
92
Clinical Guidelines
15
Public Health
8
Key Resources
8
Pharmacy & Technologies
4
Women & Child Health
3
Capacity Building
1
Toolboxes
COVID-19
198
Refugee
22
TB
9
HIV
6
Mental Health
5
Ebola
4
Conflict
4
Rapid Response
4
Pharmacy
3
NTDs
3
Health Financing Toolbox
3
NCDs
2
Zika
1
Specific Hazards
1
Global Health Education
1
AMR
1
Planetary Health
1
nterim guidance, first issued 25 January 2021, updated 15 June 2021, updated 19 November 2021, updated 23 February 2022, updated 18 August 2022
– (Comirnaty® 10 мкг або 30 мкг виробництва BioNTech/Pfizer та
AUFKLÄRUNGSMERKBLATT
Zur Schutzimpfung gegen COVID-19 (Corona Virus Disease 2019) (Grundimmunisierung und Auffrischimpfungen)
– mit mRNA-Impfstoffen –
...
Comirnaty® 10 μg und 30 μg von BioNTech / Pfizer und Spikevax® von Moderna
Stand 21. Dezember 2021
orientations provisoires, première publication le 25 janvier 2021, mise à jour le 15 juin 2021, mise à jour le 19 novembre 2021
Bisher hat die STIKO empfohlen, dass alle im Ausland mit einem nicht in der EU zugelassenen Impfstoff geimpften Personen eine erneute Impfserie mit einem in der EU zugelassenen Impfstoff erhalten sollen. Ziel der im Epidemiologischen Bulletin 13/2022 veröffentlichten aktualisierten COVID-19-Impfemp
...
Diese Faktenboxen sollen Ihnen helfen, Nutzen und Schaden einer Schutzimpfung gegen COVID-19 abzuwägen. Die Informationen und Zahlen stellen keine endgültige Bewertung dar. Sie basieren auf den derzeit besten wissenschaftlichen Erkenntnissen.
mRNA technologies. What is their future and scope, and what are the challenges that countries might face in rolling them out? Hello and welcome to Science in5. I'm Vismita Gupta-Smith. We are talking to Dr.Soumya Swaminathan today. Soumya, talk to u
...
How COVID-19 mRNA Vaccines Work
recommended
COVID-19 mRNA vaccines deliver directions to make a protein that educates our immune system, so it will neutralize the virus in future encounters. The mRNA-containing lipid particles are taken up by
...
(Comirnaty® 10 мкг або 30 мкг виробництва BioNTech/Pfizer та Spikevax® виробництва Moderna);
Anamnese zur Schutzimpfung gegen COVID-19 (Corona Virus Disease 2019) (Grundimmunisierung und Auffrischimpfungen)
– mit mRN
...
Wird ständig aktualisiert
Overview
16 Dec 2021. This interim guidance pertains to heterologous primary and heterologous boosting schedules of Covid-19 vaccines. It focuses on heterologous schedules combining multiple vaccine platforms (e.g. a vectored vaccine followed by an mRNA
...
This article was published on December 10, 2020, and updated on December 16, 2020, at NEJM.org. DOI: 10.1056/NEJMoa2034577
mRNA vaccines have to potential to end the COVID19 pandemic. How do they work? Are they safe? And how could they've been developed so quickly?
PhD Martin Moder, österreichischer Molekularbiologe, Autor populärwissenschaftlicher Bücher und Teil der Wissenschaftskabarettgruppe Science Busters, erklärt die Wirkweise und potentiellen Risiken der mRNA-Impfstoffe gegen COVID19
